Financial reports
10-K
2023 FY
Annual report
27 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
ARS
2022 FY
Annual report to shareholders
16 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
15 Mar 22
Current reports
8-K
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 24
8-K
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
30 Nov 23
8-K
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
7 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
28 Sep 23
8-K
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
10 Aug 23
8-K
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
11 May 23
8-K
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
27 Mar 23
8-K
Regulation FD Disclosure
21 Mar 23
8-K
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
28 Feb 23
8-K
Regulation FD Disclosure
20 Dec 22
Registration and prospectus
S-8
Registration of securities for employees
27 Mar 24
S-3ASR
Automatic shelf registration
28 Feb 23
S-8
Registration of securities for employees
28 Feb 23
S-8
Registration of securities for employees
15 Mar 22
424B5
Prospectus supplement for primary offering
25 Feb 21
S-3
Shelf registration
31 Dec 20
S-8
Registration of securities for employees
21 Aug 20
424B5
Prospectus supplement for primary offering
14 Jul 20
424B5
Prospectus supplement for primary offering
13 Jul 20
424B5
Prospectus supplement for primary offering
1 Jun 20
Proxies
DEF 14A
Definitive proxy
16 Aug 23
DEF 14A
Definitive proxy
16 Aug 22
DEF 14A
Definitive proxy
16 Aug 21
DEF 14A
Definitive proxy
21 Aug 20
DEF 14A
Definitive proxy
22 Aug 19
PRER14A
Preliminary revised proxy
19 Aug 19
PRE 14A
Preliminary proxy
9 Aug 19
DEF 14A
Definitive proxy
26 Jul 18
PRE 14A
Preliminary proxy
16 Jul 18
DEFA14A
Additional proxy soliciting materials
1 Sep 17
Other
CT ORDER
Confidential treatment order
29 Nov 22
EFFECT
Notice of effectiveness
12 Jan 21
UPLOAD
Letter from SEC
7 Jan 21
CORRESP
Correspondence with SEC
7 Jan 21
UPLOAD
Letter from SEC
22 Aug 19
CORRESP
Correspondence with SEC
19 Aug 19
UPLOAD
Letter from SEC
16 Aug 19
EFFECT
Notice of effectiveness
15 Apr 19
UPLOAD
Letter from SEC
15 Apr 19
CORRESP
Correspondence with SEC
11 Apr 19
Ownership
SC 13G/A
STATE STREET CORP
10 Apr 24
SC 13G
MILLENNIUM MANAGEMENT LLC
5 Mar 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
Nuveen Asset Management, LLC
14 Feb 24
SC 13G/A
TEACHERS ADVISORS, LLC
14 Feb 24
SC 13G/A
TIAA CREF INVESTMENT MANAGEMENT LLC
14 Feb 24
SC 13G
AMERIPRISE FINANCIAL INC
14 Feb 24
SC 13G/A
Avidity Partners Management LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
12 Feb 24